1	Oncor	_	NNP	_	_	8	SBJ	_	_
2	Inc.	_	NNP	_	_	1	POSTHON	_	_
3	,	_	,	_	_	1	P	_	_
4	Gaithersburg	_	NNP	_	_	1	APPO	_	_
5	,	_	,	_	_	4	P	_	_
6	Md.	_	NNP	_	_	4	APPO	_	_
7	,	_	,	_	_	1	P	_	_
8	said	_	VBD	_	_	0	ROOT	_	_
9	it	_	PRP	_	_	10	SBJ	_	_
10	received	_	VBD	_	_	8	OBJ	_	_
11	approval	_	NN	_	_	10	OBJ	_	_
12	from	_	IN	_	_	11	NMOD	_	_
13	the	_	DT	_	_	15	NMOD	_	_
14	U.S.	_	NNP	_	_	15	NAME	_	_
15	Food	_	NNP	_	_	12	PMOD	_	_
16	and	_	CC	_	_	15	COORD	_	_
17	Drug	_	NNP	_	_	18	NAME	_	_
18	Administration	_	NNP	_	_	16	CONJ	_	_
19	to	_	TO	_	_	11	NMOD	_	_
20	market	_	VB	_	_	19	IM	_	_
21	a	_	DT	_	_	23	NMOD	_	_
22	genetic	_	JJ	_	_	23	NMOD	_	_
23	test	_	NN	_	_	20	OBJ	_	_
24	that	_	WDT	_	_	25	SBJ	_	_
25	will	_	MD	_	_	23	NMOD	_	_
26	assist	_	VB	_	_	25	VC	_	_
27	in	_	IN	_	_	26	LOC	_	_
28	diagnosis	_	NN	_	_	27	PMOD	_	_
29	and	_	CC	_	_	28	COORD	_	_
30	treatment	_	NN	_	_	29	CONJ	_	_
31	of	_	IN	_	_	28	NMOD	_	_
32	leukemia	_	NN	_	_	31	PMOD	_	_
33	and	_	CC	_	_	32	COORD	_	_
34	lymph	_	NN	_	_	35	NMOD	_	_
35	cancer	_	NN	_	_	33	CONJ	_	_
36	.	_	.	_	_	8	P	_	_

1	The	_	DT	_	_	7	NMOD	_	_
2	B	_	NNP	_	_	7	NMOD	_	_
3	/	_	CC	_	_	2	COORD	_	_
4	T	_	NNP	_	_	3	CONJ	_	_
5	gene	_	NN	_	_	7	NMOD	_	_
6	rearrangement	_	NN	_	_	7	NMOD	_	_
7	test	_	NN	_	_	8	SBJ	_	_
8	is	_	VBZ	_	_	34	OBJ	_	_
9	more	_	RBR	_	_	10	AMOD	_	_
10	accurate	_	JJ	_	_	8	PRD	_	_
11	than	_	IN	_	_	10	AMOD	_	_
12	existing	_	VBG	_	_	13	NMOD	_	_
13	tests	_	NNS	_	_	11	PMOD	_	_
14	for	_	IN	_	_	8	ADV	_	_
15	diagnosing	_	VBG	_	_	14	PMOD	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	type	_	NN	_	_	15	OBJ	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	cancer	_	NN	_	_	18	PMOD	_	_
20	,	_	,	_	_	17	P	_	_
21	whether	_	IN	_	_	17	NMOD	_	_
22	it	_	PRP	_	_	23	SBJ	_	_
23	has	_	VBZ	_	_	21	SUB	_	_
24	spread	_	VBN	_	_	23	VC	_	_
25	or	_	CC	_	_	21	COORD	_	_
26	whether	_	IN	_	_	25	CONJ	_	_
27	there	_	EX	_	_	28	SBJ	_	_
28	is	_	VBZ	_	_	26	SUB	_	_
29	a	_	DT	_	_	30	NMOD	_	_
30	recurrence	_	NN	_	_	28	PRD	_	_
31	following	_	VBG	_	_	30	APPO	_	_
32	treatment	_	NN	_	_	31	OBJ	_	_
33	,	_	,	_	_	34	P	_	_
34	said	_	VBD	_	_	0	ROOT	_	_
35	Oncor	_	NNP	_	_	38	NAME	_	_
36	President	_	NNP	_	_	38	NAME	_	_
37	Stephen	_	NNP	_	_	38	NAME	_	_
38	Turner	_	NNP	_	_	34	SBJ	_	_
39	.	_	.	_	_	34	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Turner	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	test	_	NN	_	_	7	SBJ	_	_
6	initially	_	RB	_	_	7	PRP	_	_
7	will	_	MD	_	_	3	OBJ	_	_
8	be	_	VB	_	_	7	VC	_	_
9	used	_	VBN	_	_	8	VC	_	_
10	in	_	IN	_	_	9	MNR	_	_
11	conjunction	_	NN	_	_	10	PMOD	_	_
12	with	_	IN	_	_	11	NMOD	_	_
13	biopsies	_	NNS	_	_	12	PMOD	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	other	_	JJ	_	_	16	NMOD	_	_
16	tests	_	NNS	_	_	14	CONJ	_	_
17	,	_	,	_	_	7	P	_	_
18	but	_	CC	_	_	7	COORD	_	_
19	eventually	_	RB	_	_	20	TMP	_	_
20	might	_	MD	_	_	18	CONJ	_	_
21	become	_	VB	_	_	20	VC	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	benchmark	_	NN	_	_	21	PRD	_	_
24	for	_	IN	_	_	23	NMOD	_	_
25	tumor	_	NN	_	_	26	NMOD	_	_
26	analysis	_	NN	_	_	24	PMOD	_	_
27	.	_	.	_	_	3	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Turner	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	test	_	NN	_	_	6	SBJ	_	_
6	will	_	MD	_	_	3	OBJ	_	_
7	be	_	VB	_	_	6	VC	_	_
8	shipped	_	VBN	_	_	7	VC	_	_
9	in	_	IN	_	_	8	TMP	_	_
10	45	_	CD	_	_	11	NMOD	_	_
11	days	_	NNS	_	_	9	PMOD	_	_
12	to	_	TO	_	_	8	DIR	_	_
13	hospitals	_	NNS	_	_	12	PMOD	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	clinical	_	JJ	_	_	16	NMOD	_	_
16	laboratories	_	NNS	_	_	14	CONJ	_	_
17	.	_	.	_	_	3	P	_	_

1	Dr.	_	NNP	_	_	3	TITLE	_	_
2	Wyndham	_	NNP	_	_	3	NAME	_	_
3	Wilson	_	NNP	_	_	15	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	a	_	DT	_	_	8	NMOD	_	_
6	cancer	_	NN	_	_	8	NMOD	_	_
7	treatment	_	NN	_	_	8	NMOD	_	_
8	specialist	_	NN	_	_	3	APPO	_	_
9	at	_	IN	_	_	8	NMOD	_	_
10	the	_	DT	_	_	13	NMOD	_	_
11	National	_	NNP	_	_	13	NAME	_	_
12	Cancer	_	NNP	_	_	13	NAME	_	_
13	Institute	_	NNP	_	_	9	PMOD	_	_
14	,	_	,	_	_	3	P	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	test	_	NN	_	_	18	SBJ	_	_
18	is	_	VBZ	_	_	15	OBJ	_	_
19	widely	_	RB	_	_	20	ADV	_	_
20	used	_	VBN	_	_	18	VC	_	_
21	in	_	IN	_	_	20	LOC	_	_
22	research	_	NN	_	_	23	NMOD	_	_
23	centers	_	NNS	_	_	21	PMOD	_	_
24	but	_	CC	_	_	18	COORD	_	_
25	is	_	VBZ	_	_	24	CONJ	_	_
26	n't	_	RB	_	_	25	ADV	_	_
27	having	_	VBG	_	_	25	VC	_	_
28	a	_	DT	_	_	30	NMOD	_	_
29	major	_	JJ	_	_	30	NMOD	_	_
30	impact	_	NN	_	_	27	OBJ	_	_
31	because	_	IN	_	_	27	PRP	_	_
32	it	_	PRP	_	_	33	SBJ	_	_
33	is	_	VBZ	_	_	31	SUB	_	_
34	only	_	RB	_	_	33	PRD	_	_
35	occasionally	_	RB	_	_	34	AMOD	_	_
36	useful	_	JJ	_	_	34	AMOD	_	_
37	in	_	IN	_	_	34	AMOD	_	_
38	choosing	_	VBG	_	_	37	PMOD	_	_
39	the	_	DT	_	_	42	NMOD	_	_
40	most	_	JJS	_	_	41	AMOD	_	_
41	effective	_	JJ	_	_	42	NMOD	_	_
42	treatment	_	NN	_	_	38	OBJ	_	_
43	.	_	.	_	_	15	P	_	_

1	But	_	CC	_	_	4	DEP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	test	_	NN	_	_	4	SBJ	_	_
4	may	_	MD	_	_	24	OBJ	_	_
5	prove	_	VB	_	_	4	VC	_	_
6	to	_	TO	_	_	5	OPRD	_	_
7	be	_	VB	_	_	6	IM	_	_
8	more	_	RBR	_	_	9	AMOD	_	_
9	sensitive	_	JJ	_	_	7	PRD	_	_
10	in	_	IN	_	_	9	AMOD	_	_
11	determining	_	VBG	_	_	10	PMOD	_	_
12	whether	_	IN	_	_	11	OBJ	_	_
13	a	_	DT	_	_	14	NMOD	_	_
14	tumor	_	NN	_	_	15	SBJ	_	_
15	has	_	VBZ	_	_	12	SUB	_	_
16	spread	_	VBN	_	_	15	VC	_	_
17	or	_	CC	_	_	16	COORD	_	_
18	returned	_	VBN	_	_	17	CONJ	_	_
19	following	_	VBG	_	_	16	ADV	_	_
20	treatment	_	NN	_	_	19	PMOD	_	_
21	,	_	,	_	_	24	P	_	_
22	Dr.	_	NNP	_	_	23	TITLE	_	_
23	Wilson	_	NNP	_	_	24	SBJ	_	_
24	said	_	VBD	_	_	0	ROOT	_	_
25	.	_	.	_	_	24	P	_	_

1	``	_	``	_	_	17	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	do	_	VBP	_	_	17	OBJ	_	_
4	n't	_	RB	_	_	3	ADV	_	_
5	know	_	VB	_	_	3	VC	_	_
6	yet	_	RB	_	_	5	TMP	_	_
7	how	_	WRB	_	_	13	PRD	_	_
8	useful	_	JJ	_	_	7	AMOD	_	_
9	it	_	PRP	_	_	10	SBJ	_	_
10	's	_	VBZ	_	_	5	OBJ	_	_
11	going	_	VBG	_	_	10	VC	_	_
12	to	_	TO	_	_	11	VC	_	_
13	be	_	VB	_	_	12	IM	_	_
14	,	_	,	_	_	17	P	_	_
15	''	_	''	_	_	17	P	_	_
16	he	_	PRP	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

1	Oncor	_	NNP	_	_	11	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	a	_	DT	_	_	5	NMOD	_	_
4	six-year-old	_	JJ	_	_	5	NMOD	_	_
5	developer	_	NN	_	_	1	APPO	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	genetic	_	JJ	_	_	9	NMOD	_	_
8	medical	_	JJ	_	_	9	NMOD	_	_
9	tests	_	NNS	_	_	6	PMOD	_	_
10	,	_	,	_	_	1	P	_	_
11	projects	_	VBZ	_	_	33	OBJ	_	_
12	that	_	IN	_	_	11	OBJ	_	_
13	the	_	DT	_	_	15	NMOD	_	_
14	cancer	_	NN	_	_	15	NMOD	_	_
15	test	_	NN	_	_	16	SBJ	_	_
16	will	_	MD	_	_	12	SUB	_	_
17	help	_	VB	_	_	16	VC	_	_
18	it	_	PRP	_	_	17	OBJ	_	_
19	to	_	TO	_	_	17	OPRD	_	_
20	post	_	VB	_	_	19	IM	_	_
21	its	_	PRP$	_	_	23	NMOD	_	_
22	first-ever	_	JJ	_	_	23	NMOD	_	_
23	profit	_	NN	_	_	20	OBJ	_	_
24	during	_	IN	_	_	20	TMP	_	_
25	the	_	DT	_	_	27	NMOD	_	_
26	first	_	JJ	_	_	27	NMOD	_	_
27	quarter	_	NN	_	_	24	PMOD	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	1990	_	CD	_	_	28	PMOD	_	_
30	,	_	,	_	_	33	P	_	_
31	Mr.	_	NNP	_	_	32	TITLE	_	_
32	Turner	_	NNP	_	_	33	SBJ	_	_
33	said	_	VBD	_	_	0	ROOT	_	_
34	.	_	.	_	_	33	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	will	_	MD	_	_	30	OBJ	_	_
4	charge	_	VB	_	_	3	VC	_	_
5	$	_	$	_	_	4	OBJ	_	_
6	35	_	CD	_	_	5	NMOD	_	_
7	for	_	IN	_	_	4	ADV	_	_
8	a	_	DT	_	_	9	NMOD	_	_
9	test	_	NN	_	_	7	PMOD	_	_
10	and	_	CC	_	_	3	COORD	_	_
11	projects	_	VBZ	_	_	10	CONJ	_	_
12	about	_	IN	_	_	13	NMOD	_	_
13	$	_	$	_	_	11	OBJ	_	_
14	2	_	CD	_	_	13	DEP	_	_
15	million	_	CD	_	_	13	DEP	_	_
16	in	_	IN	_	_	13	NMOD	_	_
17	revenue	_	NN	_	_	16	PMOD	_	_
18	from	_	IN	_	_	13	NMOD	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	test	_	NN	_	_	18	PMOD	_	_
21	during	_	IN	_	_	13	TMP	_	_
22	the	_	DT	_	_	25	NMOD	_	_
23	first	_	JJ	_	_	25	NMOD	_	_
24	12	_	CD	_	_	25	NMOD	_	_
25	months	_	NNS	_	_	21	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	marketing	_	NN	_	_	26	PMOD	_	_
28	,	_	,	_	_	30	P	_	_
29	he	_	PRP	_	_	30	SBJ	_	_
30	said	_	VBD	_	_	0	ROOT	_	_
31	.	_	.	_	_	30	P	_	_

